Annex II — Financial tender Financial Evaluation  Title:  Reference:  Lot 5:  Vaccine effectiveness against COVID-19 and seasonal influenza among patients presenting to primary care physicians in EU/EEA Vaccine Effectiveness, Burden and Impact Studies of COVID-19 and Influenza OJ/2021/DPR/12924 Tenderer (name): The table below is automatically filled in from the first sheet. It is not editable. € 0 210 € 0 € 0 210 € 0 € 0 1 € 0 € 0 12 € 0 € 0 4 € 0 € 0 4 € 0 € 0 4 € 0 € 0 8 € 0 € 0 8 € 0 € 0 20 € 0 € 0 20 € 0 € 0 210 € 0 € 0 1 € 0 € 0 1 € 0 € 0 1 € 0 € 0 800 € 0 € 0 1 € 0 € 0 1 € 0 € 0 3 € 0 € 0 30 € 0 € 0 30 € 0 € 0 DL 5.4.6 Regular validation of datasets collected, transfer of datasets to TESSy,  validated datasets. Price for up to 15 study sites DL 5.4.7 Epidemiological data summary/bulletin  DL 5.4.8 Review adherenceto casedefinition by siteand draft report of  correctiveactions. Priceper report. DL 5.7.2 Validatethetest-negativecase-control study design for COVID-19 VE  estimation DL 5.7.3 Pland and do a random sampling study to estimateVE against  asymptomatic COVID-19 infection DL 5.4.9 Regular laboratory results summary table  DL 5.5.1 Annual report and manuscript on COVID-19 VE among outpatients.  Priceper 1 report and manuscript inclusiveopen access publication fee. DL 5.5.2 Annual report and manuscript on influenza VE among outpatients.  Priceper 1 report and manuscript inclusiveopen access publication fee. DL 5.5.3 Draft review manuscript on influenza or COVID-19 VE or methods for  assessing VE among outpatients or reviews on relevant VE-related topics. Price  per 1 manuscript inclusiveopen access publication fee. DL 5.6.1 Draft a preparedness plan and protocols for estimating VE during  influenza, coronavirusor other respiratory diseasepandemics.  DL 5.6.2 Identify additional potential study sites to beactivated during  influenza, coronavirusor other respiratory pandemics. DL 5.6.3 Pilot VE studies during theemergenceof an influenza, coronavirus or  other respiratory diseasepandemic. DL 5.7.1 Collect blood or serum samples from participants for characterisation  of theimmuneresponse. Priceper sample. DL 5.5.4 Draft summary report to support theWHO Vaccinecomposition  meeting(s) for influenza on VE among outpatients. Priceper 1 report. DL 5.5.5 Draft Summary reports on COVID-19 VE to support international  assessments such as for vaccine composition decisions. Price per 1 report. DL 5.5.6a Prepareand deliver oral presentations at European and international  scientific conferences (e.g. ESCAIDE, ESWI, ISIRV, ERS, ESCMID). Price per 1  presentation.  DL 5.5.7 Draft regular weekly summary reports for ECDCs surveillanceoutputs  (e.g. FluNewsEurope and COVID-19 weekly report). Price per weekly 1 report for  influenzaand COVID-19. DL 5.5.6b Travel to destination for DL 5.5.6a  TOTAL Reference price DL 5.7.4 Plan, implement study and report on estimated VE against influenza or  COVID-19 among children and adolescents <18 years of age.  Ad hoc consultancy: Expert day Ad hoc consultancy: Senior/Principal Expert day Page 15 of 15